To bring further innovation to industry and patients, we keep on developing our #generic API portfolio.

Having successfully finalized the entire qualification and scale-up process, we ready to enter in the market with Tucatinib. Underpinning a strong and long-lasting commercial strategy of early entering in the market offering a highly competitive timeframe, we have implemented the advanced technological manufacturing platform able to meet the customer’s request for API Tucatinib.